08 — ADC Bilingual Glossary (English ↔ Chinese)
ADC中英文术语对照表
按主题分类，附简要定义。标准缩写以括号标注。
A. ADC结构与组分 | ADC Structure & Components
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Antibody-Drug Conjugate | 抗体偶联药物 / 抗体药物偶联物 | ADC | Biologic consisting of mAb + linker + cytotoxic payload |
| Monoclonal Antibody | 单克隆抗体 | mAb | Targeting vehicle; IgG1 most common scaffold |
| Payload / Warhead | 有效载荷 / 弹头 | — | Cytotoxic agent conjugated to the antibody |
| Linker | 连接子 / 接头 | — | Chemical tether between mAb and payload; governs payload release |
| Cleavable Linker | 可裂解连接子 | CL | Linker designed to release free payload upon intracellular trigger |
| Non-Cleavable Linker | 不可裂解连接子 | NCL | Linker stable to enzymatic cleavage; payload released as catabolite after full Ab degradation |
| Drug-to-Antibody Ratio | 药抗比 | DAR | Average number of payload molecules per antibody molecule |
| Self-Immolative Spacer | 自解体间隔基 | — | Spacer (e.g., PABC) that spontaneously fragments after linker cleavage to release free payload |
| Para-Aminobenzyl Carbamate | 对氨基苄基氨基甲酸酯 | PABC | Self-immolative spacer undergoing 1,6-elimination post-linker cleavage |
| Conjugation Site | 偶联位点 | — | Amino acid residue on mAb where payload is attached (Lys, Cys, or engineered site) |
| Site-Specific Conjugation | 定点偶联 | — | Conjugation to defined mAb position → homogeneous DAR product |
| Stochastic Conjugation | 随机偶联 | — | Conjugation to heterogeneous amino acid positions → DAR mixture |
| Fc Region | Fc区 | Fc | Antibody constant region; mediates FcRn recycling, FcγR interactions |
| Fab Region | Fab区 | Fab | Antigen-binding fragment; contains CDR loops |
| CDR (Complementarity-Determining Region) | 互补决定区 | CDR | Hypervariable loops on Fab that determine antigen specificity |
| Bispecific ADC | 双特异性抗体偶联药物 | bsADC | ADC with mAb binding two different antigens or two epitopes |
B. 连接子化学 | Linker Chemistry
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Hydrazone Linker | 腙连接子 | — | Acid-labile linker cleaved at endosomal/lysosomal pH (4.5–5.5) |
| Dipeptide Linker | 二肽连接子 | — | Val-Cit or Val-Ala; cleaved by lysosomal cathepsin B |
| Valine-Citrulline | 缬氨酸-瓜氨酸 | Val-Cit | Most common dipeptide for cathepsin-cleavable linkers |
| Valine-Alanine | 缬氨酸-丙氨酸 | Val-Ala | Alternative dipeptide; faster cathepsin cleavage, more hydrophilic |
| Disulfide Linker | 二硫键连接子 | — | Cleaved by intracellular glutathione (GSH) |
| Beta-Glucuronide Linker | β-葡萄糖醛酸连接子 | — | Cleaved by beta-glucuronidase; highly hydrophilic |
| Tetrapeptide Linker | 四肽连接子 | — | GGFG sequence; used in T-DXd; cleaved by lysosomal cathepsins |
| Thioether Bond | 硫醚键 | — | Non-cleavable C–S bond formed from maleimide + thiol reaction; used in SMCC linker |
| Maleimide | 马来酰亚胺 | — | Reactive group that conjugates to cysteine thiols via Michael addition |
| Succinimide Ring | 琥珀酰亚胺环 | — | Product of maleimide-thiol reaction; can undergo retro-Michael if not ring-hydrolyzed |
| Retro-Michael Addition | 逆麦克尔加成 | — | Reverse reaction releasing maleimide-payload from succinimide adduct; driven by albumin thiol exchange |
| SMCC | SMCC | SMCC | Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate; NCL crosslinker for DM1 conjugation |
| Sulfo-SPDB | 磺基-SPDB | — | Sulfonated disulfide crosslinker for DM4; more hydrophilic than SPDB |
| CL2A | CL2A | CL2A | Carbonate-containing acid-sensitive linker used for SN-38 in sacituzumab govitecan |
| Hydrophilic Spacer (PEG) | 亲水性间隔基（PEG） | PEG | Polyethylene glycol spacer added to reduce ADC hydrophobicity at high DAR |
| Linker Stability | 连接子稳定性 | — | Resistance to premature payload release in systemic circulation |
C. 有效载荷类型 | Payload Types
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Auristatin | 奥利斯他汀 | — | Synthetic dolastatin analogue; microtubule inhibitor |
| Monomethyl Auristatin E | 单甲基奥利斯他汀E | MMAE | Membrane-permeable auristatin; strong bystander effect |
| Monomethyl Auristatin F | 单甲基奥利斯他汀F | MMAF | Charged auristatin; minimal bystander effect; used in Blenrep |
| Maytansinoid | 美登素衍生物 | — | Semi-synthetic class of tubulin inhibitors; DM1 and DM4 |
| DM1 | DM1 | DM1 | Maytansinoid; used in T-DM1 (Kadcyla); non-cleavable SMCC conjugation |
| DM4 | DM4 | DM4 | Maytansinoid; used with disulfide linker (sulfo-SPDB); cleavable; in mirvetuximab soravtansine |
| Calicheamicin | 卡奇霉素 | — | Natural enediyne; cleaves DNA via radical mechanism (DSB); used in Mylotarg/Besylomab |
| Pyrrolobenzodiazepine Dimer | 吡咯并苯并二氮䓬二聚体 | PBD | DNA interstrand crosslinker; sub-pM potency; used in Zynlonta |
| SN-38 | SN-38 | SN-38 | Active metabolite of irinotecan; Topoisomerase I inhibitor; used in Trodelvy |
| DXd (Deruxtecan) | DXd（德鲁替康） | DXd | Exatecan derivative; Topoisomerase I inhibitor; used in Enhertu; DAR ~8 |
| Duocarmycin | 倍卡霉素 | — | DNA alkylator (N3 adenine); picomolar potency; used in trastuzumab duocarmazine |
| Alpha-Amanitin | α-鹅膏毒素 | — | RNA Polymerase II inhibitor; not MDR-sensitive; used in emerging ADCs (HDP-101) |
| Microtubule Inhibitor | 微管抑制剂 | — | Payload class disrupting tubulin polymerization → mitotic arrest |
| Topoisomerase I Inhibitor | 拓扑异构酶I抑制剂 | Topo I inh. | Payload class stabilizing Topo I-DNA complex → replication fork collapse |
| DNA Double-Strand Break | DNA双链断裂 | DSB | Mechanism of calicheamicin and PBD-type payloads |
| Bystander Effect | 旁观者效应 | — | Membrane-permeable payload kills neighboring antigen-negative cells after release |
| MDR (Multi-Drug Resistance) | 多药耐药 | MDR | P-glycoprotein (P-gp/ABCB1)-mediated efflux; affects MMAE/DM1 payloads |
D. 生物分析 | Bioanalysis
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Bioanalysis | 生物分析 | BA | Measurement of drugs, metabolites, and biomarkers in biological matrices |
| Total Antibody | 总抗体 | TAb | All antibody molecules regardless of conjugation status; measured by anti-Fc capture + anti-Fab detection ELISA |
| Conjugated Antibody | 偶联抗体 | cAb | Antibody molecules bearing ≥1 payload; measured by anti-Fc capture + anti-drug detection ELISA |
| Free Payload | 游离有效载荷 / 游离药物 | — | Unconjugated cytotoxic drug in plasma; measured by LC-MS/MS |
| Conjugated Payload | 偶联有效载荷 | — | Payload molecules still attached to antibody; measured by hybrid LBA-LC/MS/MS |
| Catabolite | 分解代谢产物 | — | Intracellular degradation product of ADC (e.g., Lys-SMCC-DM1 from T-DM1) |
| Ligand-Binding Assay | 配体结合试验 | LBA | Binding-based assay (ELISA, MSD/ECL) for large molecule quantification |
| Enzyme-Linked Immunosorbent Assay | 酶联免疫吸附试验 | ELISA | Antibody-based colorimetric/chemiluminescent binding assay |
| Electrochemiluminescence | 电化学发光 | ECL | Detection technology used in MSD platform; lower matrix interference vs. colorimetric |
| Meso Scale Discovery | 美索量级检测平台 | MSD | ECL-based multi-array LBA platform widely used for ADA and PK assays |
| Liquid Chromatography–Tandem Mass Spectrometry | 液相色谱串联质谱 | LC-MS/MS | Gold standard for free payload and small molecule quantification |
| High-Resolution Mass Spectrometry | 高分辨质谱 | HRMS | Used for catabolite identification and intact ADC mass analysis |
| Hybrid LBA-LC/MS/MS | 混合配体结合-液质联用法 | Hybrid assay | Affinity capture of ADC + MS quantitation of released payload |
| Multiple Reaction Monitoring | 多反应监测 | MRM | LC-MS/MS acquisition mode for quantitative small molecule/payload assays |
| Lower Limit of Quantitation | 定量下限 | LLOQ | Lowest concentration accurately and precisely measured (≤20% CV, ±20% bias) |
| Upper Limit of Quantitation | 定量上限 | ULOQ | Highest concentration on the calibration curve |
| Minimum Required Dilution | 最低稀释倍数 | MRD | Minimum matrix dilution needed to reduce non-specific effects in LBA |
| Parallelism | 平行性 | — | Comparison of dilution linearity between incurred samples and calibrators; confirms matrix/concentration consistency |
| Hook Effect | 钩状效应 | — | Signal suppression at very high analyte concentrations in sandwich LBA; controlled by ULOQ and minimum dilution |
| Critical Reagents | 关键试剂 | CR | Biological reagents (anti-drug Ab, antigens, reference standards) that define assay performance; lot-controlled |
| Reference Standard | 参考标准品 | RS | Characterized drug material used to prepare calibrators; must match study drug DAR |
| Selectivity | 选择性 | — | Assay ability to measure analyte in presence of matrix components and related species |
| Incurred Sample Reanalysis | 回溯样品重分析 | ISR | Repeat analysis of ≥10% of study samples to confirm reproducibility; required for GCP validation |
E. 免疫原性 | Immunogenicity
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Anti-Drug Antibody | 抗药抗体 | ADA | Immune response against the ADC or its components |
| Immunogenicity | 免疫原性 | — | Propensity of a biologic to induce an immune response |
| Neutralizing Antibody | 中和抗体 | NAb | ADA that blocks drug binding to target or FcRn → reduces efficacy |
| Non-Neutralizing Antibody | 非中和抗体 | — | ADA that binds drug but does not block function; may accelerate clearance |
| Bridging Assay | 桥接试验 | — | ECL-based ADA assay using drug-biotin + drug-ruthenium to detect ADA bridging two drug molecules |
| Tiered Testing Algorithm | 分级检测策略 | — | Screen → Confirm → Titer → Characterize; standard ADA testing cascade |
| Drug Tolerance | 药物耐受性 | DT | Assay ability to detect ADA in presence of circulating drug; key challenge for ADC ADA assays |
| Acid Dissociation | 酸解离 | — | Pre-treatment of serum at pH 3.5 to dissociate ADA-drug complexes; improves drug tolerance |
| Anti-Idiotype Antibody | 抗独特型抗体 | anti-ID | Antibody against the unique antigen-binding idiotype of the therapeutic mAb; used as assay reagent |
| Neoepitope | 新表位 | — | Novel epitope created by linker-payload conjugation; can drive unique anti-linker or anti-drug-linker ADA |
| Immune Complex | 免疫复合物 | IC | ADA-ADC complex in plasma; may accelerate ADC clearance and deposit in tissues |
| HAHA / HACA | 人抗人源抗体 / 人抗嵌合体抗体 | HAHA / HACA | Human Anti-Human Antibody / Human Anti-Chimeric Antibody; older immunogenicity terms for humanized/chimeric mAbs |
F. 药代动力学 | Pharmacokinetics (PK)
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Pharmacokinetics | 药代动力学 | PK | Study of drug absorption, distribution, metabolism, and excretion (ADME) in the body |
| Area Under the Curve | 曲线下面积 | AUC | Integral of concentration-time curve; measure of total systemic exposure |
| Maximum Concentration | 峰浓度 / 最大浓度 | Cmax | Peak plasma concentration after dosing |
| Time to Maximum Concentration | 达峰时间 | Tmax | Time at which Cmax occurs |
| Trough Concentration | 谷浓度 | Ctrough | Plasma concentration just before next dose; often used in E-R analysis |
| Half-Life | 半衰期 | t½ | Time for plasma concentration to decrease by 50%; terminal phase |
| Volume of Distribution | 分布容积 | Vd | Apparent volume into which drug distributes; Vss = volume at steady state |
| Clearance | 清除率 | CL | Volume of plasma cleared of drug per unit time |
| Bioavailability | 生物利用度 | F | Fraction of dose reaching systemic circulation (IV = 100%) |
| Target-Mediated Drug Disposition | 靶标介导的药物处置 | TMDD | Non-linear PK driven by saturable binding to pharmacological target |
| FcRn (Neonatal Fc Receptor) | 新生儿Fc受体 | FcRn | Receptor mediating antibody recycling from endosomes → extends IgG half-life |
| Receptor-Mediated Endocytosis | 受体介导的内吞 | RME | Cellular uptake mechanism for ADC-antigen complex |
| Deconjugation | 脱偶联 | — | Loss of payload from the antibody in circulation; measured as TAb-cAb divergence |
| Blood-to-Plasma Ratio | 血液/血浆比 | B/P | Ratio of drug concentration in whole blood vs. plasma; affects dose calculation |
| Non-Compartmental Analysis | 非房室分析 | NCA | PK analysis without mechanistic model; derives AUC, Cmax, t½ directly from data |
| Population PK | 群体药代动力学 | popPK | Mixed-effects modeling of PK across patients; characterizes variability and covariates |
| Toxicokinetics | 毒代动力学 | TK | PK measured alongside toxicology studies; characterizes systemic exposure at tox doses |
G. 药效动力学与建模 | Pharmacodynamics & Modeling
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Pharmacodynamics | 药效动力学 | PD | Study of drug effects on the body; dose/concentration-effect relationships |
| Exposure–Response | 暴露量-效应关系 | E-R | Relationship between PK exposure metric (AUC, Cmax) and clinical outcome (efficacy or toxicity) |
| Tumor Growth Inhibition | 肿瘤生长抑制 | TGI | PK/PD metric; % reduction in tumor volume vs. control |
| Minimum Anticipated Biological Effect Level | 最低预期生物效应水平 | MABEL | Starting dose concept based on minimum biologically effective dose |
| NOAEL (No Observed Adverse Effect Level) | 未观察到不良反应的剂量 | NOAEL | Highest dose in non-clinical study without adverse effects |
| Human Equivalent Dose | 人体等效剂量 | HED | NOAEL converted to human dose using body weight/BSA scaling |
| Population PK/PD Model | 群体药代/药效模型 | popPK/PD | Model integrating PK and biomarker/efficacy data across patients |
| Transit Compartment Model | 转运房室模型 | — | PK/PD model for delayed drug effects (e.g., Friberg model for neutropenia) |
| Indirect Response Model | 间接效应模型 | IDR | PD model where drug affects production or elimination rate of response variable |
| Maximum Effect | 最大效应 | Emax | Maximum pharmacological effect achievable |
| Half-Maximal Effective Concentration | 半数有效浓度 | EC₅₀ | Concentration producing 50% of Emax |
| Half-Maximal Inhibitory Concentration | 半数抑制浓度 | IC₅₀ | Concentration inhibiting 50% of baseline response (used for cytotoxicity assays) |
| Allometric Scaling | 异速放大 / 异速缩放 | — | Scaling PK parameters across species using body weight exponents (CL ∝ BW^0.75) |
| NONMEM | NONMEM | NONMEM | Industry-standard software for nonlinear mixed-effects PK/PD modeling |
| Visual Predictive Check | 可视化预测核查 | VPC | Model diagnostic: observed data vs. simulated percentiles |
| Shrinkage | 收缩度 | — | Measure of how much individual PK estimates are pulled toward population mean; affects EBE reliability |
H. 基质与分析前变量 | Matrix & Pre-Analytical Variables
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Plasma | 血浆 | — | Liquid portion of anticoagulated blood (cells removed); preferred matrix for ADC PK |
| Serum | 血清 | — | Plasma after coagulation; contains activated proteases; generally avoided for ADC PK |
| Whole Blood | 全血 | — | Unfractionated blood; used for B/P ratio, blood cell target occupancy, ex vivo stability |
| EDTA (Ethylenediaminetetraacetic Acid) | EDTA（乙二胺四乙酸） | EDTA | Anticoagulant and metal chelator; inhibits MMPs and coagulation; K₂EDTA tube preferred |
| Sodium Fluoride | 氟化钠 | NaF | Esterase inhibitor; added to tubes for ester/carbonate linker stability |
| Hemolysis | 溶血 | — | RBC lysis releasing hemoglobin and GSH; causes assay interference and disulfide linker cleavage |
| Matrix Effect | 基质效应 | ME | Signal enhancement or suppression caused by matrix components co-eluting with analyte (LC-MS/MS) |
| Protein Precipitation | 蛋白沉淀 | PPT | Sample extraction method using organic solvent (ACN/MeOH) to remove proteins |
| Solid Phase Extraction | 固相萃取 | SPE | Sample cleanup using sorbent cartridge; selective adsorption + elution |
| Supported Liquid Extraction | 支撑液液萃取 | SLE | Hybrid technique using diatomaceous earth support for liquid-liquid partition |
| Glutathione | 谷胱甘肽 | GSH | Intracellular thiol reductant; cleaves disulfide linkers; released on hemolysis |
| Carboxylesterase | 羧酸酯酶 | CES | Enzyme hydrolyzing ester bonds; high in rat plasma → critical for ester-linker ADC stability in rat studies |
| Cathepsin B | 组织蛋白酶B | CatB | Lysosomal cysteine protease; cleaves Val-Cit/Val-Ala linkers; key intracellular ADC activator |
| Matrix Metalloproteinase | 基质金属蛋白酶 | MMP | Zinc-dependent protease in tumor stroma and neutrophils; inhibited by EDTA |
| Beta-Glucuronidase | β-葡萄糖醛酸酶 | β-GUS | Lysosomal/tumor enzyme cleaving glucuronide linkers; elevated in tumor necrosis |
| Myeloperoxidase | 髓过氧化物酶 | MPO | Neutrophil enzyme; can oxidize maleimide or payload; released on neutrophil activation |
| Platelet-Poor Plasma | 乏血小板血浆 | PPP | Double-centrifuged plasma with minimal platelet contamination; reduces cathepsin B contamination |
| Freeze-Thaw Cycle | 冻融循环 | F-T | Repeated freezing and thawing; must be validated (≥3 cycles per ICH M10) |
| Bench-Top Stability | 台面稳定性 | — | Stability of analyte in matrix at room temperature; must cover sample processing time |
I. 监管法规 | Regulatory
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Bioanalytical Method Validation | 生物分析方法验证 | BMV | Formal process establishing assay performance (per ICH M10/FDA guidance) |
| Good Laboratory Practice | 良好实验室规范 | GLP | Quality system for non-clinical safety studies; required for pivotal toxicology studies |
| Good Clinical Practice | 良好临床规范 | GCP | Quality standard for clinical trials; required for all clinical bioanalytical assays |
| Fit-for-Purpose | 适配目的 | FFP | Qualification approach for exploratory/early-stage assays not yet fully validated |
| Investigational New Drug Application | 新药临床试验申请 | IND | US regulatory filing to begin human clinical trials |
| Clinical Trial Application | 临床试验申请 | CTA | EU equivalent of IND |
| New Drug Application | 新药申请 | NDA | US regulatory filing for small molecule drug approval |
| Biologics License Application | 生物制品许可申请 | BLA | US regulatory filing for biologic (including ADC) approval |
| Marketing Authorization Application | 上市许可申请 | MAA | EU regulatory filing for drug approval (EMA) |
| Summary of Clinical Pharmacology | 临床药理学概述 | — | NDA/BLA Module 2.7.2; includes PK methods and E-R analyses |
| Common Technical Document | 通用技术文件 | CTD | Standardized ICH format for regulatory submissions globally |
| ICH M10 | ICH M10 | M10 | ICH Bioanalytical Method Validation guideline (2022); global harmonized standard |
| ICH S9 | ICH S9 | S9 | Nonclinical safety guidance for anticancer drugs; allows abbreviated tox package |
| ICH M3(R2) | ICH M3(R2) | M3(R2) | Nonclinical study timing relative to clinical development |
| ICH E8(R1) | ICH E8(R1) | E8(R1) | General considerations for design of clinical studies |
| MABEL | 最低预期生物效应水平 | MABEL | EMA/CHMP approach for FIH dose determination in high-risk biologics |
| Safety Margin | 安全余量 | — | Ratio of NOAEL exposure (in most sensitive species) to projected human efficacious exposure |
| Tissue Cross-Reactivity | 组织交叉反应性 | TCR | IHC study on human normal tissue panel to assess off-target antigen binding |
| Pharmacovigilance | 药物警戒 | PV | Post-marketing safety monitoring system |
| Risk Management Plan | 风险管理计划 | RMP | EU document outlining identified risks and mitigation strategies |
J. 临床终点与疗效生物标志物 | Clinical Endpoints & Efficacy Biomarkers
| English Term | 中文术语 | Abbreviation | Brief Definition / 简要释义 |
|---|---|---|---|
| Objective Response Rate | 客观缓解率 | ORR | % of patients achieving PR + CR per RECIST criteria |
| Complete Response | 完全缓解 | CR | No detectable tumor by imaging |
| Partial Response | 部分缓解 | PR | ≥30% reduction in tumor size (RECIST) |
| Stable Disease | 疾病稳定 | SD | Neither sufficient shrinkage (PR) nor growth (PD) |
| Progressive Disease | 疾病进展 | PD | ≥20% increase in tumor size or new lesion |
| Disease Control Rate | 疾病控制率 | DCR | ORR + SD rate |
| Progression-Free Survival | 无进展生存期 | PFS | Time from treatment start to disease progression or death |
| Overall Survival | 总生存期 | OS | Time from treatment start to death from any cause |
| Pathologic Complete Response | 病理完全缓解 | pCR | No residual invasive tumor in surgical specimen; key endpoint for neoadjuvant ADC trials |
| Soluble Target Antigen | 可溶性靶抗原 | sTAA | Shed extracellular domain circulating in plasma; decoy for ADC; measured as PD biomarker |
| Tumor Antigen Expression | 肿瘤抗原表达 | — | IHC/ISH quantitation of target on tumor tissue; determines patient eligibility |
| Circulating Tumor DNA | 循环肿瘤DNA | ctDNA | Cell-free tumor-derived DNA in plasma; used for minimal residual disease and resistance monitoring |
| Pharmacodynamic Biomarker | 药效动力学生物标志物 | PD biomarker | Measurable change in patient reflecting drug’s biological effect (e.g., γH2AX for DNA DSB) |
| Predictive Biomarker | 预测性生物标志物 | — | Biomarker that predicts differential response to a specific treatment |
| Prognostic Biomarker | 预后性生物标志物 | — | Biomarker that predicts patient outcome regardless of treatment |
K. 常用ADC药物名称对照 | Approved ADC Drug Names
| Brand Name | 中文名 / 音译名 | INN | Target |
|---|---|---|---|
| Mylotarg | 麦罗塔 / 吉妥珠单抗奥唑米星 | Gemtuzumab ozogamicin | CD33 |
| Kadcyla | 赫赛莱 / 恩美曲妥珠单抗 | Ado-trastuzumab emtansine (T-DM1) | HER2 |
| Adcetris | 安适利 / 维布妥昔单抗 | Brentuximab vedotin | CD30 |
| Polivy | 普利维 / 维泊妥珠单抗 | Polatuzumab vedotin | CD79b |
| Padcev | 帕德赛 / 恩诺单抗 | Enfortumab vedotin | Nectin-4 |
| Trodelvy | 拓达维 / 戈沙妥珠单抗 | Sacituzumab govitecan | TROP-2 |
| Enhertu | 优赫得 / 德曲妥珠单抗 | Trastuzumab deruxtecan (T-DXd) | HER2 |
| Zynlonta | 赞洛塔 / 朗卡妥昔单抗替西林 | Loncastuximab tesirine | CD19 |
| Blenrep | 贝伦雷普 / 贝兰他单抗马法多汀 | Belantamab mafodotin | BCMA |
| Elahere | 艾拉赫 / 米维妥珠单抗索拉坦辛 | Mirvetuximab soravtansine | FRα |
| Besylomab | 贝司洛单抗 / 奥加伊妥珠单抗 | Inotuzumab ozogamicin | CD22 |
| Tivdak | 替弗达克 / 替沙妥昔单抗 | Tisotumab vedotin | TF (Tissue Factor) |